[
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-01 06:08:20",
    "publisher": "Reuters",
    "title": "Japan health ministry panel backs Eli Lilly dementia drug donanemab",
    "image": "https://images.financialmodelingprep.com/news/japan-health-ministry-panel-backs-eli-lilly-dementia-drug-20240801.jpg",
    "site": "reuters.com",
    "text": "A Japanese health ministry panel on Thursday recommended approval for Eli Lilly's dementia treatment donanemab.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/japan-health-ministry-panel-backs-eli-lilly-dementia-drug-donanemab-2024-08-01/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-01T06:08:20-04:00",
    "date_et": "2024-08-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-01 06:45:00",
    "publisher": "PRNewsWire",
    "title": "Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity",
    "image": "https://images.financialmodelingprep.com/news/lillys-tirzepatide-successful-in-phase-3-study-showing-benefit-20240801.jpg",
    "site": "prnewswire.com",
    "text": "Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization , oral diuretic intensification or cardiovascular death – by 38% compared to placebo Tirzepatide significantly improved heart failure symptoms and physical limitations Tirzepatide led to 15.7% weight loss in a combined population of people with and without type 2 diabetes  INDIANAPOLIS , Aug. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. Tirzepatide demonstrated statistically significant improvements in both primary endpoints with a reduction in the risk of heart failure outcomes, assessed as a composite endpoint, and improvements in heart failure symptoms and physical limitations, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS),i compared with placebo.",
    "url": "https://www.prnewswire.com/news-releases/lillys-tirzepatide-successful-in-phase-3-study-showing-benefit-in-adults-with-heart-failure-with-preserved-ejection-fraction-and-obesity-302211753.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-01T06:45:00-04:00",
    "date_et": "2024-08-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-01 06:48:55",
    "publisher": "Reuters",
    "title": "Lilly says weight loss drug cut heart failure risk by 38% in trial",
    "image": "https://images.financialmodelingprep.com/news/lilly-says-weight-loss-drug-cut-heart-failure-risk-20240801.jpg",
    "site": "reuters.com",
    "text": "Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-says-weight-loss-drug-cut-heart-failure-risk-by-38-trial-2024-08-01/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-01T06:48:55-04:00",
    "date_et": "2024-08-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-01 07:41:20",
    "publisher": "Investopedia",
    "title": "What You Need to Know Ahead of Eli Lilly Earnings",
    "image": "https://images.financialmodelingprep.com/news/what-you-need-to-know-ahead-of-eli-lilly-20240801.jpg",
    "site": "investopedia.com",
    "text": "Eli Lilly (LLY) reports earnings before markets open on August 8, with analysts projecting revenue and profits to be boosted by the popularity of the weight-loss drugs Mounjaro and Zepbound.",
    "url": "https://www.investopedia.com/what-you-need-to-know-ahead-of-eli-lilly-earnings-8686801",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-01T07:41:20-04:00",
    "date_et": "2024-08-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-01 10:00:00",
    "publisher": "Accesswire",
    "title": "MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!",
    "image": "https://images.financialmodelingprep.com/news/morf-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-20240801.jpg",
    "site": "accesswire.com",
    "text": "NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (\"Morphic\") (NASDAQ:MORF) and Eli Lilly and Company (\"Eli Lilly\") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.",
    "url": "https://www.accesswire.com/viewarticle.aspx?id=893310&lang=en",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-01T10:00:00-04:00",
    "date_et": "2024-08-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-01 10:29:00",
    "publisher": "Barrons",
    "title": "Eli Lilly Finds Another Condition for Zepbound to Treat. The Stock Is Up.",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-finds-another-condition-for-zepbound-to-treat-20240801.jpg",
    "site": "barrons.com",
    "text": "The drug appears to have hit a home run treating a common form of heart failure.",
    "url": "https://www.barrons.com/articles/eli-lilly-stock-zepbound-weight-loss-drug-f3a47d01",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-01T10:29:00-04:00",
    "date_et": "2024-08-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-01 11:06:44",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-lly-earnings-expected-to-grow-what-to-20240801.jpg",
    "site": "zacks.com",
    "text": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://www.zacks.com/stock/news/2314332/eli-lilly-lly-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2314332",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-01T11:06:44-04:00",
    "date_et": "2024-08-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-01 12:30:51",
    "publisher": "Investopedia",
    "title": "Eli Lilly Weight-Loss Drug Could Also Treat Heart Failure, Study Shows",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-weightloss-drug-could-also-treat-heart-failure-20240801.jpg",
    "site": "investopedia.com",
    "text": "The active ingredient in Eli Lilly's (LLY) flagship weight-loss drug has a new potential indication: heart failure treatment.",
    "url": "https://www.investopedia.com/eli-lilly-weight-loss-drug-could-also-treat-heart-failure-study-shows-8687314",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-01T12:30:51-04:00",
    "date_et": "2024-08-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-01 13:13:56",
    "publisher": "Reuters",
    "title": "Lilly CEO says weight-loss drug shortage to end 'very soon', Bloomberg News reports",
    "image": "https://images.financialmodelingprep.com/news/lilly-ceo-says-weightloss-drug-shortage-to-end-very-20240801.jpg",
    "site": "reuters.com",
    "text": "U.S. drugmaker Eli Lilly expects its blockbuster weight-loss drug to officially come out of shortage in the United States in coming days, Bloomberg News reported on Thursday, citing an interview with the company's chief executive officer, David Ricks.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-ceo-says-weight-loss-drug-shortage-end-very-soon-bloomberg-news-reports-2024-08-01/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-01T13:13:56-04:00",
    "date_et": "2024-08-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-01 15:20:05",
    "publisher": "InvestorPlace",
    "title": "What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.",
    "image": "https://images.financialmodelingprep.com/news/what-are-the-hottest-weight-loss-stocks-right-now-20240801.jpg",
    "site": "investorplace.com",
    "text": "Easily one of the biggest trends right now in the field of medicine is the weight loss drug surge. Without attempting to sound cynical, the reality is that the sector enjoys a massive total addressable market.",
    "url": "https://investorplace.com/2024/08/what-are-the-hottest-weight-loss-stocks-right-now-3-top-picks/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-01T15:20:05-04:00",
    "date_et": "2024-08-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-01 18:35:01",
    "publisher": "The Motley Fool",
    "title": "Why Eli Lilly Stock Trounced the Market on Thursday",
    "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-stock-trounced-the-market-on-thursday-20240801.jpg",
    "site": "fool.com",
    "text": "The pharmaceutical giant's CEO had some very good news to report about a hot product. The medication should come off the FDA's shortage list in the immediate future, according to him.",
    "url": "https://www.fool.com/investing/2024/08/01/why-eli-lilly-stock-trounced-the-market-on-thursda/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-01T18:35:01-04:00",
    "date_et": "2024-08-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-02 10:00:00",
    "publisher": "Accesswire",
    "title": "MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!",
    "image": "https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240802.jpg",
    "site": "accesswire.com",
    "text": "NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (\"Morphic\") (NASDAQ:MORF) and Eli Lilly and Company (\"Eli Lilly\") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.",
    "url": "https://www.accesswire.com/viewarticle.aspx?id=893311&lang=en",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-02T10:00:00-04:00",
    "date_et": "2024-08-02"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-02 14:48:37",
    "publisher": "Reuters",
    "title": "US FDA says all doses of Lilly's weight-loss and diabetes drug now available",
    "image": "https://images.financialmodelingprep.com/news/us-fda-says-all-doses-of-lillys-weightloss-and-20240802.jpg",
    "site": "reuters.com",
    "text": "All doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-says-all-doses-lillys-weight-loss-diabetes-drug-now-available-2024-08-02/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-02T14:48:37-04:00",
    "date_et": "2024-08-02"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-02 16:00:00",
    "publisher": "GlobeNewsWire",
    "title": "Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses",
    "image": "https://images.financialmodelingprep.com/news/calling-all-morphic-holding-inc-morf-investors-contact-bronstein-20240802.jpg",
    "site": "globenewswire.com",
    "text": "NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ: MORF) and Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.",
    "url": "https://www.globenewswire.com/news-release/2024/08/02/2923819/9788/en/Calling-All-Morphic-Holding-Inc-MORF-Investors-Contact-Bronstein-Gewirtz-Grossman-LLC-To-Claim-Your-Losses.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-02T16:00:00-04:00",
    "date_et": "2024-08-02"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-02 16:22:38",
    "publisher": "CNBC",
    "title": "Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA says",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-zepbound-and-mounjaro-now-available-in-us-20240802.jpg",
    "site": "cnbc.com",
    "text": "All doses of Eli Lilly's highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the Food and Drug Administration's drug shortage database. The update comes one day after Eli Lilly CEO David Ricks said shortages of Mounjaro and Zepbound would end \"very soon.",
    "url": "https://www.cnbc.com/2024/08/02/eli-lilly-zepbound-mounjaro-available-after-shortages.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-02T16:22:38-04:00",
    "date_et": "2024-08-02"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-03 04:10:00",
    "publisher": "The Motley Fool",
    "title": "Is This Decision by Pfizer Bad News for Eli Lilly?",
    "image": "https://images.financialmodelingprep.com/news/is-this-decision-by-pfizer-bad-news-for-eli-20240803.jpg",
    "site": "fool.com",
    "text": "Eli Lilly is a giant in the world of weight loss drugs, generating billions of dollars in revenue. Rival big pharma player Pfizer aims to get in on this major market.",
    "url": "https://www.fool.com/investing/2024/08/03/is-this-decision-by-pfizer-bad-news-for-eli-lilly/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-03T04:10:00-04:00",
    "date_et": "2024-08-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-03 06:20:00",
    "publisher": "The Motley Fool",
    "title": "Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-vs-novo-nordisk-a-recent-study-suggests-20240803.jpg",
    "site": "fool.com",
    "text": "A recent study compared the effectiveness of tirzepatide against semaglutide. Tirzepatide has been more effective in helping people lose weight in trials, and the study corroborated that.",
    "url": "https://www.fool.com/investing/2024/08/03/eli-lilly-vs-novo-nordisk-a-recent-study-suggests/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-03T06:20:00-04:00",
    "date_et": "2024-08-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-04 05:26:00",
    "publisher": "The Motley Fool",
    "title": "Eli Lilly's Obesity Drug Shows a Heart Benefit. Is It Time to Buy?",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-obesity-drug-shows-a-heart-benefit-is-it-20240804.jpg",
    "site": "fool.com",
    "text": "A clinical trial starring patients with both obesity and heart failure says treatment with tirzepatide provides a big risk reduction. Tirzepatide is the active ingredient in both Mounjaro, a diabetes treatment, and Zepbound, a weight-management drug.",
    "url": "https://www.fool.com/investing/2024/08/04/eli-lilly-a-buy-now/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-04T05:26:00-04:00",
    "date_et": "2024-08-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-04 09:00:00",
    "publisher": "Seeking Alpha",
    "title": "Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-i-expect-strong-q2-earnings-but-the-20240804.jpg",
    "site": "seekingalpha.com",
    "text": "My initial bearish thesis about Eli Lilly stock did not age well, as the stock has performed well since February despite being substantially overvalued. However, the market appears to be comfortable with the overvaluation as long as the company continues to capitalize on strong demand momentum for its diabetes and obesity drugs. Apart from the strong momentum of its stellar products like Mounjaro and Zepbound, there are several additional developments that contribute to my optimism.",
    "url": "https://seekingalpha.com/article/4710215-eli-lilly-i-expect-strong-q2-earnings-but-the-valuation-is-already-optimistic",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-04T09:00:00-04:00",
    "date_et": "2024-08-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-04 10:00:00",
    "publisher": "Accesswire",
    "title": "MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!",
    "image": "https://images.financialmodelingprep.com/news/morf-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-20240804.jpg",
    "site": "accesswire.com",
    "text": "NEW YORK, NY / ACCESSWIRE / August 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (\"Morphic\") (NASDAQ:MORF) and Eli Lilly and Company (\"Eli Lilly\") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.",
    "url": "https://www.accesswire.com/viewarticle.aspx?id=893312&lang=en",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-04T10:00:00-04:00",
    "date_et": "2024-08-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-05 05:10:00",
    "publisher": "The Motley Fool",
    "title": "Should You Buy Eli Lilly Before Aug. 8?",
    "image": "https://images.financialmodelingprep.com/news/should-you-buy-eli-lilly-before-aug-8-20240805.jpg",
    "site": "fool.com",
    "text": "Eli Lilly shares have soared more than 230% over the past three years. The company has generated major growth thanks to its weight loss drugs.",
    "url": "https://www.fool.com/investing/2024/08/05/should-you-buy-eli-lilly-before-aug-8/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-05T05:10:00-04:00",
    "date_et": "2024-08-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-05 06:06:47",
    "publisher": "Reuters",
    "title": "Lilly, Novo Nordisk battle for weight-loss market lands at the pharmacy shelf",
    "image": "https://images.financialmodelingprep.com/news/lilly-novo-nordisk-battle-for-weightloss-market-lands-at-20240805.jpg",
    "site": "reuters.com",
    "text": "As Eli Lilly's weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk's Wegovy, some doctors say their guiding principle for writing prescriptions is simple: which drug can my patients actually get at the pharmacy?",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-novo-nordisk-battle-weight-loss-market-lands-pharmacy-shelf-2024-08-05/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-05T06:06:47-04:00",
    "date_et": "2024-08-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-05 08:00:29",
    "publisher": "Investors Business Daily",
    "title": "10 Imploding Stocks Cost Investors A Staggering $2 Trillion",
    "image": "https://images.financialmodelingprep.com/news/10-imploding-stocks-cost-investors-a-staggering-2-trillion-20240805.jpg",
    "site": "investors.com",
    "text": "The S&P 500 is down \"only\" 6.1% since its July 16 high. So why does the drop feel so bad?",
    "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-imploding-stocks-cost-investors-a-staggering-2-trillion/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-05T08:00:29-04:00",
    "date_et": "2024-08-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-05 10:00:00",
    "publisher": "Accesswire",
    "title": "MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!",
    "image": "https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240805.jpg",
    "site": "accesswire.com",
    "text": "NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (\"Morphic\") (NASDAQ:MORF) and Eli Lilly and Company (\"Eli Lilly\") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.",
    "url": "https://www.accesswire.com/viewarticle.aspx?id=893313&lang=en",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-05T10:00:00-04:00",
    "date_et": "2024-08-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-05 10:21:33",
    "publisher": "Zacks Investment Research",
    "title": "Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures",
    "image": "https://images.financialmodelingprep.com/news/lilly-lly-q2-earnings-on-the-horizon-analysts-insights-20240805.jpg",
    "site": "zacks.com",
    "text": "Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.",
    "url": "https://www.zacks.com/stock/news/2315866/lilly-lly-q2-earnings-on-the-horizon-analysts-insights-on-key-performance-measures?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2315866",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-05T10:21:33-04:00",
    "date_et": "2024-08-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-05 10:41:18",
    "publisher": "Zacks Investment Research",
    "title": "Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?",
    "image": "https://images.financialmodelingprep.com/news/should-you-buy-sell-or-hold-lilly-lly-ahead-20240805.jpg",
    "site": "zacks.com",
    "text": "Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.",
    "url": "https://www.zacks.com/stock/news/2316000/should-you-buy-sell-or-hold-lilly-lly-ahead-of-q2-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2316000",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-05T10:41:18-04:00",
    "date_et": "2024-08-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-05 12:41:02",
    "publisher": "Zacks Investment Research",
    "title": "Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?",
    "image": "https://images.financialmodelingprep.com/news/will-these-5-medical-stocks-surpass-q2-earnings-forecasts-20240805.jpg",
    "site": "zacks.com",
    "text": "Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.",
    "url": "https://www.zacks.com/stock/news/2316241/will-these-5-medical-stocks-surpass-q2-earnings-forecasts?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview_esp-2316241",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-05T12:41:02-04:00",
    "date_et": "2024-08-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-06 03:20:00",
    "publisher": "Seeking Alpha",
    "title": "The Final Peak Week Of The Q2 Season Begins Amid Souring Economic Data",
    "image": "https://images.financialmodelingprep.com/news/the-final-peak-week-of-the-q2-season-begins-20240806.jpg",
    "site": "seekingalpha.com",
    "text": "This marks the last peak week of the Q2 earnings season with 3,908 companies expected to report. Earnings have come in better-than-expected, but tend to be overshadowed by economic data. Outlier earnings this week include: CSX, CAT, and VFC.",
    "url": "https://seekingalpha.com/article/4710731-final-peak-week-q2-season-begins-souring-economic-data",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-06T03:20:00-04:00",
    "date_et": "2024-08-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-06 05:34:00",
    "publisher": "The Motley Fool",
    "title": "Prediction: These Could Be the Best-Performing Value Stocks Through 2030",
    "image": "https://images.financialmodelingprep.com/news/prediction-these-could-be-the-bestperforming-value-stocks-through-20240806.jpg",
    "site": "fool.com",
    "text": "These value-oriented businesses are also faithful dividend payers. Eli Lilly has scored multiple wins in recent months, and this established pharmaceutical giant is looking increasingly attractive for a long-term investment.",
    "url": "https://www.fool.com/investing/2024/08/06/prediction-these-could-be-the-best-performing-valu/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-06T05:34:00-04:00",
    "date_et": "2024-08-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-06 09:53:00",
    "publisher": "The Motley Fool",
    "title": "Prediction: This Will Be the Best Pharmaceutical Stock to Own Over the Next 10 Years",
    "image": "https://images.financialmodelingprep.com/news/prediction-this-will-be-the-best-pharmaceutical-stock-to-20240806.jpg",
    "site": "fool.com",
    "text": "Eli Lilly is a leader in diabetes and obesity care through its medications Mounjaro and Zepbound. Now, it's also set to enter the $31 billion Alzheimer's market following FDA approval of donanemab.",
    "url": "https://www.fool.com/investing/2024/08/06/prediction-this-will-be-the-best-pharmaceutical/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-06T09:53:00-04:00",
    "date_et": "2024-08-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-06 10:00:00",
    "publisher": "Accesswire",
    "title": "MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!",
    "image": "https://images.financialmodelingprep.com/news/morf-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-an-20240806.jpg",
    "site": "accesswire.com",
    "text": "NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (\"Morphic\") (NASDAQ:MORF) and Eli Lilly and Company (\"Eli Lilly\") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.",
    "url": "https://www.accesswire.com/viewarticle.aspx?id=893314&lang=en",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-06T10:00:00-04:00",
    "date_et": "2024-08-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-06 10:00:23",
    "publisher": "Forbes",
    "title": "Will The Supply Shortage Weigh On Eli Lilly's Q2?",
    "image": "https://images.financialmodelingprep.com/news/will-the-supply-shortage-weigh-on-eli-lillys-q2-20240806.jpg",
    "site": "forbes.com",
    "text": "Eli Lilly stock (NYSE: LLY) will report its Q2 results on Thursday, August 8. The pharmaceutical giant is expected to garner $10 billion in sales and $2.70 in adjusted earnings per share, per the consensus estimates.",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/08/06/will-the-supply-shortage-weigh-on-eli-lillys-q2/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-06T10:00:23-04:00",
    "date_et": "2024-08-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-06 11:10:57",
    "publisher": "Zacks Investment Research",
    "title": "Can Mounjaro & Zepbound Drive Eli Lilly (LLY) Q2 Earnings?",
    "image": "https://images.financialmodelingprep.com/news/can-mounjaro-zepbound-drive-eli-lilly-lly-q2-earnings-20240806.jpg",
    "site": "zacks.com",
    "text": "Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.",
    "url": "https://www.zacks.com/stock/news/2317100/can-mounjaro-zepbound-drive-eli-lilly-lly-q2-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview-2317100",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-06T11:10:57-04:00",
    "date_et": "2024-08-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-06 19:31:40",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly (LLY) & Novo Nordisk (NVO) Earnings: A Closer Look",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-lly-novo-nordisk-nvo-earnings-a-closer-20240806.jpg",
    "site": "zacks.com",
    "text": "Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.",
    "url": "https://www.zacks.com/stock/news/2317485/eli-lilly-lly-novo-nordisk-nvo-earnings-a-closer-look?cid=CS-STOCKNEWSAPI-FT-stocks_in_the_news-2317485",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-06T19:31:40-04:00",
    "date_et": "2024-08-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-07 09:26:25",
    "publisher": "Benzinga",
    "title": "How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings",
    "image": "https://images.financialmodelingprep.com/news/how-to-earn-500-a-month-from-eli-lilly-stock-20240807.jpg",
    "site": "benzinga.com",
    "text": "Eli Lilly and Company LLY is expected to release earnings results for its second quarter, before the opening bell on Thursday, Aug. 8.",
    "url": "https://www.benzinga.com/news/earnings/24/08/40221288/how-to-earn-500-a-month-from-eli-lilly-stock-ahead-of-q2-earnings",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-07T09:26:25-04:00",
    "date_et": "2024-08-07"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-07 10:00:00",
    "publisher": "Accesswire",
    "title": "MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!",
    "image": "https://images.financialmodelingprep.com/news/morf-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-20240807.jpg",
    "site": "accesswire.com",
    "text": "NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (\"Morphic\") (NASDAQ:MORF) and Eli Lilly and Company (\"Eli Lilly\") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.",
    "url": "https://www.accesswire.com/viewarticle.aspx?id=893315&lang=en",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-07T10:00:00-04:00",
    "date_et": "2024-08-07"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-07 15:28:24",
    "publisher": "Benzinga",
    "title": "Eli Lilly: Bearish Signals Loom Over Weight Loss Stock Ahead Of Q2 Earnings",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-bearish-signals-loom-over-weight-loss-stock-20240807.jpg",
    "site": "benzinga.com",
    "text": "Eli Lilly and Co LLY will be reporting its second-quarter earnings on Thursday. Wall Street expects $2.70 in EPS and $9.9 billion in revenues as the company reports before market hours.",
    "url": "https://www.benzinga.com/general/health-care/24/08/40231406/eli-lilly-bearish-signals-loom-over-weight-loss-stock-ahead-of-q2-earnings",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-07T15:28:24-04:00",
    "date_et": "2024-08-07"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-07 16:30:00",
    "publisher": "Barrons",
    "title": "Eli Lilly Reports Earnings Thursday Amid a Stock Slump",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-reports-earnings-thursday-amid-a-stock-slump-20240807.jpg",
    "site": "barrons.com",
    "text": "Investors will be looking for updates on Zepbound's rollout, and projections for when supply shortages in the U.S. might end.",
    "url": "https://www.barrons.com/articles/eli-lilly-earnings-stock-price-302f0681",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-07T16:30:00-04:00",
    "date_et": "2024-08-07"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 01:04:43",
    "publisher": "The Motley Fool",
    "title": "Here's Why Eli Lilly Stock Dropped 12% Last Month",
    "image": "https://images.financialmodelingprep.com/news/heres-why-eli-lilly-stock-dropped-12-last-month-20240808.jpg",
    "site": "fool.com",
    "text": "A rival pharmaceutical company released promising clinical trial results from a weight-loss treatment. Eli Lilly is one of two companies dominating the obesity drug market right now.",
    "url": "https://www.fool.com/investing/2024/08/08/heres-why-eli-lilly-stock-dropped-12-last-month/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T01:04:43-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 05:00:00",
    "publisher": "GlobeNewsWire",
    "title": "Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly",
    "image": "https://images.financialmodelingprep.com/news/defiance-launches-llyx-the-first-2x-leveraged-singlestock-etf-20240808.jpg",
    "site": "globenewswire.com",
    "text": "MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs proudly unveils LLYX, the world's first single-stock leveraged ETF for Eli Lilly. LLYX offers retail investors 2X daily long leveraged exposure to the change in the daily share price of Eli Lilly without the need for a margin account, providing a unique tool for tactical traders.",
    "url": "https://www.globenewswire.com/news-release/2024/08/08/2926655/0/en/Defiance-Launches-LLYX-the-First-2X-Leveraged-Single-Stock-ETF-on-Eli-Lilly.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T05:00:00-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 06:45:00",
    "publisher": "PRNewsWire",
    "title": "Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion",
    "image": "https://images.financialmodelingprep.com/news/lilly-reports-q2-2024-financial-results-raises-fullyear-revenue-20240808.jpg",
    "site": "prnewswire.com",
    "text": "Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%.",
    "url": "https://www.prnewswire.com/news-releases/lilly-reports-q2-2024-financial-results-raises-full-year-revenue-guidance-by-3-billion-302217339.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T06:45:00-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 06:51:09",
    "publisher": "Reuters",
    "title": "Eli Lilly raises annual profit forecast as Zepbound quarterly sales cross $1 billion",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-raises-annual-profit-forecast-as-zepbound-quarterly-sales-20240808.jpg",
    "site": "reuters.com",
    "text": "Eli Lilly on Thursday raised its annual profit forecast and sales of its popular weight-loss drug Zepbound crossed $1 billion for the first time in a quarter.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-raises-annual-profit-forecast-zepbound-quarterly-sales-cross-1-billion-2024-08-08/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T06:51:09-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 06:56:00",
    "publisher": "Market Watch",
    "title": "Eli Lilly's stock leaps after big earnings beat, boosted by strength in Mounjaro and Zepbound sales",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-stock-leaps-after-big-earnings-beat-boosted-20240808.jpg",
    "site": "marketwatch.com",
    "text": "Shares of Eli Lilly & Co. LLY, -2.65% shot up 8.5% in premarket trading Thursday, after the drug maker reported second-quarter earnings that rose well above forecasts, boosted by strength in its diabetes and obesity treatments, Mounjaro and Zepbound and by higher prices. Net income jumped to $2.97 billion, or $3.28 a share, from $1.76 billion, or $1.95 a share, in the same period a year ago.",
    "url": "https://www.marketwatch.com/story/eli-lillys-stock-leaps-after-big-earnings-beat-boosted-by-strength-in-mounjaro-and-zepbound-sales-1fbaa675",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T06:56:00-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 06:57:10",
    "publisher": "CNBC",
    "title": "Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-blows-past-estimates-hikes-guidance-as-zepbound-20240808.jpg",
    "site": "cnbc.com",
    "text": "Eli Lilly reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound spike. The drugmaker now expects full-year adjusted earnings of $16.10 to $16.60, up from a previous guidance of $13.50 to $14 per share.",
    "url": "https://www.cnbc.com/2024/08/08/eli-lilly-lly-earnings-q2-2024.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T06:57:10-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 07:10:51",
    "publisher": "FXEmpire",
    "title": "Blockbuster Drugs Drive Eli Lilly's Strong Q2 Performance",
    "image": "https://images.financialmodelingprep.com/news/blockbuster-drugs-drive-eli-lillys-strong-q2-performance-20240808.jpg",
    "site": "fxempire.com",
    "text": "Eli Lilly reports Q2 EPS of $3.92, exceeding expectations. Revenue reaches $11.30 billion, driven by strong drug sales.",
    "url": "https://www.fxempire.com/news/article/blockbuster-drugs-drive-eli-lillys-strong-q2-performance-1452175",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T07:10:51-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 07:21:53",
    "publisher": "Forbes",
    "title": "Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales Soar",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-surges-on-strong-earnings-as-mounjaro-and-20240808.jpg",
    "site": "forbes.com",
    "text": "Pharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro, smashing analysts' expectations in the face of growing competition in the lucrative weight loss drug market as it struggles to boost supplies and tackle shortages.",
    "url": "https://www.forbes.com/sites/roberthart/2024/08/08/eli-lilly-surges-on-strong-earnings-as-mounjaro-and-zepbound-sales-soar/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T07:21:53-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 08:31:40",
    "publisher": "Proactive Investors",
    "title": "Nasdaq and S&P 500 to open flat as recession fears grow; Eli Lilly rallies",
    "image": "https://images.financialmodelingprep.com/news/nasdaq-and-sp-500-to-open-flat-as-recession-20240808.jpg",
    "site": "proactiveinvestors.com",
    "text": "8.30am: Wall Street to open flat US markets are set to open flat today, with stocks struggling to stabilise as recession fears were renewed and carry trades continued to unwind.  The Dow Jones is shifting slightly lower in premarket futures, predicted to open 46 points lower at 38,864.",
    "url": "https://www.proactiveinvestors.com/companies/news/1053688",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T08:31:40-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 08:46:42",
    "publisher": "Investopedia",
    "title": "Eli Lilly Stock Soars as Mounjaro, Zepbound Power Earnings Beat, Guidance Boost",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-soars-as-mounjaro-zepbound-power-earnings-20240808.jpg",
    "site": "investopedia.com",
    "text": "Eli Lilly (LLY) shares surged higher in premarket trading Thursday after the drugmaker's second-quarter earnings came in well above analysts' estimates and it raised its full-year revenue and profit guidance.",
    "url": "https://www.investopedia.com/eli-lilly-stock-soars-as-mounjaro-zepbound-power-earnings-beat-guidance-boost-8692355",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T08:46:42-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 08:55:39",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly (LLY) Surpasses Q2 Earnings and Revenue Estimates",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-lly-surpasses-q2-earnings-and-revenue-estimates-20240808.jpg",
    "site": "zacks.com",
    "text": "Eli Lilly (LLY) came out with quarterly earnings of $3.92 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.11 per share a year ago.",
    "url": "https://www.zacks.com/stock/news/2318864/eli-lilly-lly-surpasses-q2-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2318864",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T08:55:39-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 10:00:00",
    "publisher": "Accesswire",
    "title": "MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!",
    "image": "https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240808.jpg",
    "site": "accesswire.com",
    "text": "NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (\"Morphic\") (NASDAQ:MORF) and Eli Lilly and Company (\"Eli Lilly\") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.",
    "url": "https://www.accesswire.com/viewarticle.aspx?id=893316&lang=en",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T10:00:00-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 10:28:36",
    "publisher": "Schaeffers Research",
    "title": "Options Bulls Target Eli Lilly Stock After Beat-and-Raise",
    "image": "https://images.financialmodelingprep.com/news/options-bulls-target-eli-lilly-stock-after-beatandraise-20240808.jpg",
    "site": "schaeffersresearch.com",
    "text": "Eli Lilly And Co   (NYSE:LLY) surpassed top- and bottom-line expectations for the second quarter, and lifted its full-year revenue outlook by $3 billion amid strong sales of weight loss drug and diabetes drugs Zepbound and Mounjaro.",
    "url": "https://www.schaeffersresearch.com/content/news/2024/08/08/options-bulls-target-eli-lilly-stock-after-beat-and-raise",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T10:28:36-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 10:35:43",
    "publisher": "Zacks Investment Research",
    "title": "Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics",
    "image": "https://images.financialmodelingprep.com/news/compared-to-estimates-lilly-lly-q2-earnings-a-look-20240808.jpg",
    "site": "zacks.com",
    "text": "Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://www.zacks.com/stock/news/2319091/compared-to-estimates-lilly-lly-q2-earnings-a-look-at-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2319091",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T10:35:43-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 10:52:14",
    "publisher": "Kiplinger",
    "title": "Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-weightloss-drugs-fuel-beatandraise-quarter-20240808.jpg",
    "site": "kiplinger.com",
    "text": "Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know.",
    "url": "https://www.kiplinger.com/investing/stocks/eli-lillys-lly-weight-loss-drugs-fuel-beat-and-raise-quarter",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T10:52:14-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 11:07:38",
    "publisher": "Fox Business",
    "title": "Eli Lilly raises forecast after boost in Zepbound, Mounjaro sales",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-raises-forecast-after-boost-in-zepbound-mounjaro-20240808.jpg",
    "site": "foxbusiness.com",
    "text": "Eli Lilly and Co. reported strong second-quarter results, beating Wall Street estimates and prompting the company to raise its full-year revenue forecast by $3 billion.",
    "url": "https://www.foxbusiness.com/lifestyle/eli-lilly-raises-forecast-after-boost-zepbound-mounjaro-sales",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T11:07:38-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 11:30:24",
    "publisher": "Zacks Investment Research",
    "title": "Continuing Claims Hit Highest Since Nov 2021",
    "image": "https://images.financialmodelingprep.com/news/continuing-claims-hit-highest-since-nov-2021-20240808.jpg",
    "site": "zacks.com",
    "text": "It's a big day for Wall Street as the much-awaited Jobless Claims numbers are out, which could be a major factor in market moves for the rest of the week. Right now, stock futures are climbing up as the weekly jobless claims numbers have come in better than expected.",
    "url": "https://www.zacks.com/stock/news/2319303/continuing-claims-hit-highest-since-nov-2021?cid=CS-STOCKNEWSAPI-FT-economic_highlights-2319303",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T11:30:24-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 11:55:26",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly (LLY) Q2 Earnings Top, Mounjaro, Zepbound Drive View",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-lly-q2-earnings-top-mounjaro-zepbound-drive-20240808.jpg",
    "site": "zacks.com",
    "text": "Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.",
    "url": "https://www.zacks.com/stock/news/2319330/eli-lilly-lly-q2-earnings-top-mounjaro-zepbound-drive-view?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2319330",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T11:55:26-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 12:06:32",
    "publisher": "Benzinga",
    "title": "Dow Jumps Over 500 Points; Eli Lilly Posts Upbeat Earnings",
    "image": "https://images.financialmodelingprep.com/news/dow-jumps-over-500-points-eli-lilly-posts-upbeat-20240808.jpg",
    "site": "benzinga.com",
    "text": "U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 500 points on Thursday.",
    "url": "https://www.benzinga.com/news/earnings/24/08/40259926/dow-jumps-over-500-points-eli-lilly-posts-upbeat-earnings",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T12:06:32-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 13:37:08",
    "publisher": "The Motley Fool",
    "title": "Why Eli Lilly Stock Just Jumped 8%",
    "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-stock-just-jumped-8-20240808.jpg",
    "site": "fool.com",
    "text": "Powered by Mounjaro and Zepbound, Lilly announced staggering sales and earnings growth this morning. The weight loss drug business is so good, Lilly also raised its full-year sales forecast by $3 billion.",
    "url": "https://www.fool.com/investing/2024/08/08/why-eli-lilly-stock-just-jumped-8/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T13:37:08-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 14:31:08",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly: The Next $1 Trillion Market Cap Stock?",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-the-next-1-trillion-market-cap-stock-20240808.jpg",
    "site": "zacks.com",
    "text": "Eli Lilly ( LLY ) reported strong quarterly results on Thursaday morning, with revenue increasing 36%, driven primarily by the success of Mounjaro, Zepbound, and Verzenio. The company also saw a significant increase in earnings per share (EPS), up 68% year-on-year and eclipsing analysts' estimates by 42%.",
    "url": "https://www.zacks.com/commentary/2319475/eli-lilly-the-next-1-trillion-market-cap-stock?cid=CS-STOCKNEWSAPI-FT-investment_ideas-2319475",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T14:31:08-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 16:00:00",
    "publisher": "GlobeNewsWire",
    "title": "Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses",
    "image": "https://images.financialmodelingprep.com/news/calling-all-morphic-holding-inc-morf-investors-contact-bronstein-gewirtz-20240808.jpg",
    "site": "globenewswire.com",
    "text": "NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ: MORF) and Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.",
    "url": "https://www.globenewswire.com/news-release/2024/08/08/2927268/9788/en/Calling-All-Morphic-Holding-Inc-MORF-Investors-Contact-Bronstein-Gewirtz-Grossman-LLC-To-Claim-Your-Losses.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T16:00:00-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 16:55:48",
    "publisher": "Investopedia",
    "title": "4 Key Takeaways From Eli Lilly's Earnings",
    "image": "https://images.financialmodelingprep.com/news/4-key-takeaways-from-eli-lillys-earnings-20240808.jpg",
    "site": "investopedia.com",
    "text": "Eli Lilly (LLY) shares soared Thursday, after the company's second-quarter earnings surpassed expectations on booming demand for its weight-loss drugs and executives provided updates on production capacity and more.",
    "url": "https://www.investopedia.com/key-takeaways-from-eli-lilly-earnings-q2-fy-2024-8692583",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T16:55:48-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 17:26:17",
    "publisher": "Investopedia",
    "title": "S&P 500 Gains and Losses Today: Eli Lilly Soars on Growing Demand for Weight-Loss Drugs",
    "image": "https://images.financialmodelingprep.com/news/sp-500-gains-and-losses-today-eli-lilly-soars-on-20240808.jpg",
    "site": "investopedia.com",
    "text": "Major U.S. equities indexes rallied after jobless claims data released Thursday helped ease worries about the economy. The S&P 500 jumped 2.3%, marking the strongest daily performance for the benchmark index since November 2022.",
    "url": "https://www.investopedia.com/s-and-p-500-gains-and-losses-today-eli-lilly-soars-on-growing-demand-for-weight-loss-drugs-8692853",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T17:26:17-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-08 18:16:47",
    "publisher": "CNBC",
    "title": "After Eli Lilly's blowout quarter, Cramer says not to get too caught up in macro market trends",
    "image": "https://images.financialmodelingprep.com/news/after-eli-lillys-blowout-quarter-cramer-says-not-to-get-20240808.jpg",
    "site": "cnbc.com",
    "text": "CNBC's Jim Cramer on Thursday recommended that investors not base portfolio decisions solely off of macro economic trends, like new employment data or interest rates. He discussed pharmaceutical giant Eli Lilly's blow-out quarter, saying its success is not due to general attitudes on the market.",
    "url": "https://www.cnbc.com/2024/08/08/after-eli-lillys-quarter-cramer-says-dont-just-focus-on-macro-trends.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-08T18:16:47-04:00",
    "date_et": "2024-08-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-09 06:02:00",
    "publisher": "The Motley Fool",
    "title": "2 Healthcare Stocks to Buy Hand Over Fist in August",
    "image": "https://images.financialmodelingprep.com/news/2-healthcare-stocks-to-buy-hand-over-fist-in-20240809.jpg",
    "site": "fool.com",
    "text": "Eli Lilly is a leader in diabetes and obesity care, but it's also making progress elsewhere. Johnson & Johnson has a robust underlying business, and a rare and ongoing dividend streak.",
    "url": "https://www.fool.com/investing/2024/08/09/2-healthcare-stocks-buy-hand-over-fist-in-august/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-09T06:02:00-04:00",
    "date_et": "2024-08-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-09 07:00:09",
    "publisher": "MarketBeat",
    "title": "It's Too Soon to Buy the Dip in Weight Loss Drugmakers",
    "image": "https://images.financialmodelingprep.com/news/its-too-soon-to-buy-the-dip-in-weight-20240809.jpg",
    "site": "marketbeat.com",
    "text": "Obesity drugmakers like Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO were not immune to the broad market sell-off sparked by the June CPI report, but investors looking to get into these names should be cheering. The stocks are down 20% or more from their highs, offering big discounts and the opportunity for fat profits over the long term.",
    "url": "https://www.marketbeat.com/originals/its-too-soon-to-buy-the-dip-in-weight-loss-drugmakers/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-09T07:00:09-04:00",
    "date_et": "2024-08-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-09 08:14:00",
    "publisher": "Market Watch",
    "title": "These stocks join Meta and Eli Lilly as the biggest winners this earnings season",
    "image": "https://images.financialmodelingprep.com/news/these-stocks-join-meta-and-eli-lilly-as-the-20240809.jpg",
    "site": "marketwatch.com",
    "text": "We're nearing the end of second-quarter earnings season, so this is a good moment to screen the S&P 500 and show which companies increased revenue the most while also improving their profit margins.",
    "url": "https://www.marketwatch.com/story/these-stocks-join-meta-and-eli-lilly-as-the-biggest-winners-this-earnings-season-0ab5cead",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-09T08:14:00-04:00",
    "date_et": "2024-08-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-09 10:00:00",
    "publisher": "Accesswire",
    "title": "MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!",
    "image": "https://images.financialmodelingprep.com/news/morf-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-an-20240809.jpg",
    "site": "accesswire.com",
    "text": "NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (\"Morphic\") (NASDAQ:MORF) and Eli Lilly and Company (\"Eli Lilly\") (NYSE:LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.",
    "url": "https://www.accesswire.com/viewarticle.aspx?id=893317&lang=en",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-09T10:00:00-04:00",
    "date_et": "2024-08-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-09 12:02:42",
    "publisher": "InvestorPlace",
    "title": "3 Healthcare Stocks to Sell in August Before They Crash & Burn",
    "image": "https://images.financialmodelingprep.com/news/3-healthcare-stocks-to-sell-in-august-before-they-20240809.jpg",
    "site": "investorplace.com",
    "text": "The stock market is currently in a rotation. Traders are moving capital from aggressive growth and technology names to find safety in other sectors of the market.",
    "url": "https://investorplace.com/2024/08/3-healthcare-stocks-to-sell-in-august-before-they-crash-burn/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-09T12:02:42-04:00",
    "date_et": "2024-08-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-09 12:16:11",
    "publisher": "24/7 Wall Street",
    "title": "3 Dynamite Stocks to Load Up On For the Next Major Bull Market Rally",
    "image": "https://images.financialmodelingprep.com/news/3-dynamite-stocks-to-load-up-on-for-the-20240809.jpg",
    "site": "247wallst.com",
    "text": "Long-term stocks, or those that are meant to be held for over a year, let investors ignore daily market fluctuations.",
    "url": "https://247wallst.com/investing/2024/08/09/3-dynamite-stocks-to-load-up-on-for-the-next-major-bull-market-rally/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-09T12:16:11-04:00",
    "date_et": "2024-08-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-09 14:50:38",
    "publisher": "Investopedia",
    "title": "Eli Lilly Stock Keeps Climbing After Drugmaker's Strong Earnings Report",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-keeps-climbing-after-drugmakers-strong-earnings-report-20240809.jpg",
    "site": "investopedia.com",
    "text": "Investors of Eli Lilly (LLY) continued to ride the wave created by the pharmaceutical firm's powerhouse second-quarter earnings report.",
    "url": "https://www.investopedia.com/eli-lilly-stock-keeps-climbing-after-drugmaker-s-strong-earnings-report-8693349",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-09T14:50:38-04:00",
    "date_et": "2024-08-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-09 16:03:04",
    "publisher": "Benzinga",
    "title": "Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-q2-sales-surge-36-analysts-cautious-on-20240809.jpg",
    "site": "benzinga.com",
    "text": "Eli Lilly And Co LLY reported on Thursday second-quarter revenue of $11.3 billion, up 36% year-over-year, easily surpassing the consensus of $9.95 billion.",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40294656/eli-lillys-q2-sales-surge-36-analysts-cautious-on-future-supply-market-dynamics-opt",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-09T16:03:04-04:00",
    "date_et": "2024-08-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-10 06:32:00",
    "publisher": "InvestorPlace",
    "title": "3 Stocks to Load-Up On Before Autumn Arrives",
    "image": "https://images.financialmodelingprep.com/news/3-stocks-to-loadup-on-before-autumn-arrives-20240810.jpg",
    "site": "investorplace.com",
    "text": "Despite the volatility seen this summer, certain stocks are managing to outperform the broader market. Strong second-quarter financial results and positive forward guidance have propelled some stocks ahead of their peers and are leading to big gains for their shareholders.",
    "url": "https://investorplace.com/2024/08/3-stocks-to-load-up-on-before-autumn-arrives-2/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-10T06:32:00-04:00",
    "date_et": "2024-08-10"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-11 09:05:00",
    "publisher": "The Motley Fool",
    "title": "A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.",
    "image": "https://images.financialmodelingprep.com/news/a-blood-test-could-detect-early-alzheimers-that-could-20240811.jpg",
    "site": "fool.com",
    "text": "A blood test that checks for an abnormal protein could detect 90% of Alzheimer's cases. Eli Lilly recently obtained approval for an early Alzheimer's treatment, Kisunla.",
    "url": "https://www.fool.com/investing/2024/08/11/a-blood-test-could-detect-early-alzheimers-that-co/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-11T09:05:00-04:00",
    "date_et": "2024-08-11"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-11 10:00:00",
    "publisher": "Accesswire",
    "title": "MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Clients to Contact the Firm!",
    "image": "https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240811.jpg",
    "site": "accesswire.com",
    "text": "NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (\"Morphic\") (NASDAQ:MORF) and Eli Lilly and Company (\"Eli Lilly\") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.",
    "url": "https://www.accesswire.com/viewarticle.aspx?id=893318&lang=en",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-11T10:00:00-04:00",
    "date_et": "2024-08-11"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-12 09:15:00",
    "publisher": "The Motley Fool",
    "title": "Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move",
    "image": "https://images.financialmodelingprep.com/news/prediction-buying-biotech-and-pharma-stocks-during-this-selloff-will-20240812.jpg",
    "site": "fool.com",
    "text": "The recent sell-off brought biopharma stocks down by a bit. Nothing has changed about their ability to compete.",
    "url": "https://www.fool.com/investing/2024/08/12/prediction-buying-biotech-and-pharma-stocks-during/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-12T09:15:00-04:00",
    "date_et": "2024-08-12"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-12 09:37:09",
    "publisher": "Seeking Alpha",
    "title": "Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-triggers-our-confirmed-buy-signal-technical-analysis-20240812.jpg",
    "site": "seekingalpha.com",
    "text": "Eli Lilly and Company triggered a Buy signal after a price pop from the latest earnings report. Technical Buy signals, including Full Stochastic and MACD crossover, indicate upward momentum and potential test of the recent high in price. Portfolio managers may need to sell Eli Lilly stock due to high exposure, potentially slowing bounce in a bear market.",
    "url": "https://seekingalpha.com/article/4713690-eli-lilly-triggers-our-confirmed-buy-signal-technical-analysis",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-12T09:37:09-04:00",
    "date_et": "2024-08-12"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-12 09:46:00",
    "publisher": "Benzinga",
    "title": "Eli Lilly To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-to-rally-around-15-here-are-10-20240812.jpg",
    "site": "benzinga.com",
    "text": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.",
    "url": "https://www.benzinga.com/news/24/08/40313853/eli-lilly-to-rally-around-15-here-are-10-top-analyst-forecasts-for-monday",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-12T09:46:00-04:00",
    "date_et": "2024-08-12"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-12 10:15:47",
    "publisher": "24/7 Wall Street",
    "title": "Is Eli Lilly a Stock To Buy and Hold Forever?",
    "image": "https://images.financialmodelingprep.com/news/is-eli-lilly-a-stock-to-buy-and-hold-forever-20240812.jpg",
    "site": "247wallst.com",
    "text": "Holding a promising future due to recent success in the obesity drug market, Eli Lilly (NYSE:LLY) appears to be bound for continued gains.",
    "url": "https://247wallst.com/investing/2024/08/12/is-eli-lilly-a-stock-to-buy-and-hold-forever/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-12T10:15:47-04:00",
    "date_et": "2024-08-12"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-12 10:21:58",
    "publisher": "Zacks Investment Research",
    "title": "International Markets and Lilly (LLY): A Deep Dive for Investors",
    "image": "https://images.financialmodelingprep.com/news/international-markets-and-lilly-lly-a-deep-dive-for-20240812.jpg",
    "site": "zacks.com",
    "text": "Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.",
    "url": "https://www.zacks.com/stock/news/2320553/international-markets-and-lilly-lly-a-deep-dive-for-investors?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_international_revenues-2320553",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-12T10:21:58-04:00",
    "date_et": "2024-08-12"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-12 12:18:29",
    "publisher": "Seeking Alpha",
    "title": "Eli Lilly Q2 Earnings: Thanks To Tirzepatide, $1 Trillion Valuation Now In Sight",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-q2-earnings-thanks-to-tirzepatide-1-trillion-20240812.jpg",
    "site": "seekingalpha.com",
    "text": "Eli Lilly and Company reported strong Q2 2024 earnings with revenues up 36% year-on-year, exceeding expectations. Guidance for 2024 was raised by ~$3bn with expectations of $45.4bn — $46.6bn in revenues and EPS of $15.1 — $15.6 on a GAAP basis. Tirzepatide, a key revenue contributor, shows enormous potential in the diabetes and weight loss markets, driving Lilly's share price and market cap valuation.",
    "url": "https://seekingalpha.com/article/4713730-eli-lilly-q2-earnings-thanks-to-tirzepatide-1-trillion-valuation-now-in-sight",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-12T12:18:29-04:00",
    "date_et": "2024-08-12"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-12 12:52:04",
    "publisher": "Zacks Investment Research",
    "title": "5 ETFs to Make the Most of Eli Lilly's Strength",
    "image": "https://images.financialmodelingprep.com/news/5-etfs-to-make-the-most-of-eli-lillys-20240812.jpg",
    "site": "zacks.com",
    "text": "Impressed by Eli Lilly's (LLY) blowout earnings, several analysts raised their target price on the stock.",
    "url": "https://www.zacks.com/stock/news/2320811/5-etfs-to-make-the-most-of-eli-lilly-s-strength?cid=CS-STOCKNEWSAPI-FT-etf_news_and_commentary-2320811",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-12T12:52:04-04:00",
    "date_et": "2024-08-12"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-12 14:58:18",
    "publisher": "Investors Business Daily",
    "title": "Funds Load Up On Costco, Eli Lilly, These Other Stocks",
    "image": "https://images.financialmodelingprep.com/news/funds-load-up-on-costco-eli-lilly-these-other-20240812.jpg",
    "site": "investors.com",
    "text": "Fund managers have been busy buying amid the ongoing market weakness. Four stocks are near buy points or are building bases.",
    "url": "https://www.investors.com/research/costco-stock-netflix-stock-fund-buys/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-12T14:58:18-04:00",
    "date_et": "2024-08-12"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-12 18:01:19",
    "publisher": "Investopedia",
    "title": "Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-finishes-lower-after-news-of-bond-20240812.jpg",
    "site": "investopedia.com",
    "text": "Eli Lilly (LLY) shares finished Monday lower after a back-and-forth session in which an analyst upgrade sent them higher before news of $5 billion in bond sales pulled them into the red.",
    "url": "https://www.investopedia.com/eli-lilly-will-sell-usd5-billion-in-bonds-to-fund-morphic-acquisition-8694234",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-12T18:01:19-04:00",
    "date_et": "2024-08-12"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-12 19:05:57",
    "publisher": "Zacks Investment Research",
    "title": "Should Investors Buy Eli Lilly's (LLY) Stock After Strong Q2 Results?",
    "image": "https://images.financialmodelingprep.com/news/should-investors-buy-eli-lillys-lly-stock-after-strong-20240812.jpg",
    "site": "zacks.com",
    "text": "As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.",
    "url": "https://www.zacks.com/commentary/2320976/should-investors-buy-eli-lilly-s-lly-stock-after-strong-q2-results?cid=CS-STOCKNEWSAPI-FT-investment_ideas-2320976",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-12T19:05:57-04:00",
    "date_et": "2024-08-12"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-13 05:50:00",
    "publisher": "The Motley Fool",
    "title": "Why Eli Lilly Stock's Big Jump Last Week Could Be Just the Beginning of Another Huge Run",
    "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-stocks-big-jump-last-week-could-be-20240813.jpg",
    "site": "fool.com",
    "text": "Lilly's Mounjaro and Zepbound are only warming up. The company has several other promising drugs in its lineup and pipeline.",
    "url": "https://www.fool.com/investing/2024/08/13/why-eli-lilly-stocks-big-jump-last-week-could-be-j/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-13T05:50:00-04:00",
    "date_et": "2024-08-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-13 07:05:00",
    "publisher": "The Motley Fool",
    "title": "This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock",
    "image": "https://images.financialmodelingprep.com/news/this-1-piece-of-good-news-for-eli-lilly-is-20240813.jpg",
    "site": "fool.com",
    "text": "Eli Lilly claims that it's finally producing enough of its weight loss drugs. Companies producing substitutes for those drugs may have trouble growing soon.",
    "url": "https://www.fool.com/investing/2024/08/13/this-1-piece-good-news-for-eli-lilly-is-bad-news-f/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-13T07:05:00-04:00",
    "date_et": "2024-08-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-13 08:00:00",
    "publisher": "PRNewsWire",
    "title": "Lilly opens state-of-the-art research and development center in the Boston Seaport",
    "image": "https://images.financialmodelingprep.com/news/lilly-opens-stateoftheart-research-and-development-center-in-the-20240813.jpg",
    "site": "prnewswire.com",
    "text": "Lilly Seaport Innovation Center (LSC) serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Gateway Labs New 346,000 square foot facility will accommodate approximately 500 Lilly scientists and researchers, in addition to 200 people from Lilly Gateway Labs' companies INDIANAPOLIS , Aug. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration and chronic pain. \"The opening of LSC expands upon Lilly's long-standing presence in the Boston area,\" said Daniel Skovronsky, M.D.",
    "url": "https://www.prnewswire.com/news-releases/lilly-opens-state-of-the-art-research-and-development-center-in-the-boston-seaport-302219992.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-13T08:00:00-04:00",
    "date_et": "2024-08-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-13 08:00:24",
    "publisher": "Forbes",
    "title": "What's Next For Eli Lilly Stock After A Solid Q2?",
    "image": "https://images.financialmodelingprep.com/news/whats-next-for-eli-lilly-stock-after-a-solid-20240813.jpg",
    "site": "forbes.com",
    "text": "Eli Lilly stock (NYSE: LLY) recently reported its Q2 results, with revenues and earnings exceeding the street expectations. The pharmaceutical giant reported sales of $11.3 billion and adjusted earnings of $3.92 per share, compared to the consensus estimates of $9.9 billion and $2.60, respectively.",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/08/13/whats-next-for-eli-lilly-stock-after-a-solid-q2/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-13T08:00:24-04:00",
    "date_et": "2024-08-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-13 10:06:26",
    "publisher": "Zacks Investment Research",
    "title": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know",
    "image": "https://images.financialmodelingprep.com/news/investors-heavily-search-eli-lilly-and-company-lly-here-20240813.jpg",
    "site": "zacks.com",
    "text": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://www.zacks.com/stock/news/2321168/investors-heavily-search-eli-lilly-and-company-lly-here-is-what-you-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2321168",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-13T10:06:26-04:00",
    "date_et": "2024-08-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-13 10:08:54",
    "publisher": "InvestorPlace",
    "title": "3 Stocks on the Rise After Stellar Q2 Earnings Results",
    "image": "https://images.financialmodelingprep.com/news/3-stocks-on-the-rise-after-stellar-q2-earnings-20240813.jpg",
    "site": "investorplace.com",
    "text": "A large majority of the companies have already reported second-quarter results. While we can call it a mixed earnings season, there are a few companies that beat expectations and reported record revenue and profits.",
    "url": "https://investorplace.com/2024/08/3-stocks-on-the-rise-after-stellar-q2-earnings-results/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-13T10:08:54-04:00",
    "date_et": "2024-08-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-13 10:31:16",
    "publisher": "Zacks Investment Research",
    "title": "Wall Street Analysts See Lilly (LLY) as a Buy: Should You Invest?",
    "image": "https://images.financialmodelingprep.com/news/wall-street-analysts-see-lilly-lly-as-a-buy-20240813.jpg",
    "site": "zacks.com",
    "text": "The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.",
    "url": "https://www.zacks.com/stock/news/2321243/wall-street-analysts-see-lilly-lly-as-a-buy-should-you-invest?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|average_broker_rating-2321243",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-13T10:31:16-04:00",
    "date_et": "2024-08-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-13 11:31:00",
    "publisher": "Market Watch",
    "title": "Lilly, Uber among the biggest recent winners of the beat-and-raise game in the stock market",
    "image": "https://images.financialmodelingprep.com/news/lilly-uber-among-the-biggest-recent-winners-of-the-20240813.jpg",
    "site": "marketwatch.com",
    "text": "For U.S. stocks, quarterly earnings seasons are set up to follow an old “beat-and-raise” pattern, which can lift share prices. A look ahead at earnings estimates for 2025 highlights a group of companies whose earnings estimates have been raised the most.",
    "url": "https://www.marketwatch.com/story/lilly-uber-among-the-biggest-recent-winners-of-the-beat-and-raise-game-in-the-stock-market-274080dd",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-13T11:31:00-04:00",
    "date_et": "2024-08-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-13 11:32:01",
    "publisher": "Zacks Investment Research",
    "title": "3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View",
    "image": "https://images.financialmodelingprep.com/news/3-big-drug-stocks-to-watch-on-raised-2024-earnings-20240813.jpg",
    "site": "zacks.com",
    "text": "Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.",
    "url": "https://www.zacks.com/stock/news/2321388/3-big-drug-stocks-to-watch-on-raised-2024-earnings-sales-view?cid=CS-STOCKNEWSAPI-FT-analyst_blog|investment_ideas-2321388",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-13T11:32:01-04:00",
    "date_et": "2024-08-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-13 13:00:50",
    "publisher": "Zacks Investment Research",
    "title": "Lilly (LLY) Upgraded to Buy: Here's Why",
    "image": "https://images.financialmodelingprep.com/news/lilly-lly-upgraded-to-buy-heres-why-20240813.jpg",
    "site": "zacks.com",
    "text": "Lilly (LLY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
    "url": "https://www.zacks.com/stock/news/2321510/lilly-lly-upgraded-to-buy-here-s-why?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2321510",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-13T13:00:50-04:00",
    "date_et": "2024-08-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-13 13:14:00",
    "publisher": "The Motley Fool",
    "title": "Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs",
    "image": "https://images.financialmodelingprep.com/news/prediction-the-next-big-biotech-stock-boom-will-be-in-20240813.jpg",
    "site": "fool.com",
    "text": "Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.",
    "url": "https://www.fool.com/investing/2024/08/13/the-next-big-biotech-stock-boom-will-be-longevity/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-13T13:14:00-04:00",
    "date_et": "2024-08-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-14 06:35:00",
    "publisher": "The Motley Fool",
    "title": "Up 10% in 1 Day, Is It Too Late to Buy Eli Lilly Stock?",
    "image": "https://images.financialmodelingprep.com/news/up-10-in-1-day-is-it-too-late-20240814.jpg",
    "site": "fool.com",
    "text": "The market reacted very positively to Eli Lilly's Q2 earnings report. This isn't the first time the stock has seen a significant run-up in a short period.",
    "url": "https://www.fool.com/investing/2024/08/14/up-10-in-1-day-is-it-too-late-to-buy-eli-lilly-sto/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-14T06:35:00-04:00",
    "date_et": "2024-08-14"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-14 10:36:13",
    "publisher": "Zacks Investment Research",
    "title": "Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?",
    "image": "https://images.financialmodelingprep.com/news/is-eli-lilly-lly-a-buy-post-stellar-q2-20240814.jpg",
    "site": "zacks.com",
    "text": "Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.",
    "url": "https://www.zacks.com/stock/news/2321929/is-eli-lilly-lly-a-buy-post-stellar-q2-earnings-raised-view?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2321929",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-14T10:36:13-04:00",
    "date_et": "2024-08-14"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-14 11:15:12",
    "publisher": "Reuters",
    "title": "Lilly demands doctors stop selling copycat weight-loss drugs, Bloomberg reports",
    "image": "https://images.financialmodelingprep.com/news/lilly-demands-doctors-stop-selling-copycat-weightloss-drugs-bloomberg-20240814.jpg",
    "site": "reuters.com",
    "text": "Eli Lilly has sent cease-and-desist letters to US healthcare providers in recent days demanding they stop promoting copycat weight-loss drugs as the supply of the company's drug Zepbound improves, Bloomberg News reported on Wednesday.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-demands-doctors-stop-selling-copycat-weight-loss-drugs-bloomberg-reports-2024-08-14/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-14T11:15:12-04:00",
    "date_et": "2024-08-14"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-15 06:00:00",
    "publisher": "InvestorPlace",
    "title": "3 Biotech Stocks to Buy on the Dip: August 2024",
    "image": "https://images.financialmodelingprep.com/news/3-biotech-stocks-to-buy-on-the-dip-august-2024-20240815.jpg",
    "site": "investorplace.com",
    "text": "With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many of the most prominent biomedical developers see their stock price rise or fall based on their drug success.",
    "url": "https://investorplace.com/2024/08/3-biotech-stocks-to-buy-on-the-dip-august-2024/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-15T06:00:00-04:00",
    "date_et": "2024-08-15"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-15 12:45:42",
    "publisher": "Investors Business Daily",
    "title": "Is Eli Lilly Stock A Buy Or A Sell After FDA Delays Its Alzheimer's Drug Decision?",
    "image": "https://images.financialmodelingprep.com/news/is-eli-lilly-stock-a-buy-or-a-sell-20240405.jpg",
    "site": "investors.com",
    "text": "The FDA will now hold an advisory committee meeting to discuss Eli Lilly's Alzheimer's drug, donanemab. Is Eli Lilly stock a buy or a sell?",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-buy-now/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-15T12:45:42-04:00",
    "date_et": "2024-08-15"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-15 13:02:04",
    "publisher": "Zacks Investment Research",
    "title": "What Makes Eli Lilly (LLY) a Strong Momentum Stock: Buy Now?",
    "image": "https://images.financialmodelingprep.com/news/what-makes-eli-lilly-lly-a-strong-momentum-stock-20240815.jpg",
    "site": "zacks.com",
    "text": "Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.",
    "url": "https://www.zacks.com/stock/news/2322724/what-makes-eli-lilly-lly-a-strong-momentum-stock-buy-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_10-2322724",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-15T13:02:04-04:00",
    "date_et": "2024-08-15"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-16 08:38:00",
    "publisher": "PRNewsWire",
    "title": "Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease",
    "image": "https://images.financialmodelingprep.com/news/lilly-completes-acquisition-of-morphic-to-improve-outcomes-and-expand-20240816.jpg",
    "site": "prnewswire.com",
    "text": "Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).",
    "url": "https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-morphic-to-improve-outcomes-and-expand-options-for-people-living-with-inflammatory-bowel-disease-302224347.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-16T08:38:00-04:00",
    "date_et": "2024-08-16"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-16 11:16:05",
    "publisher": "Zacks Investment Research",
    "title": "3 Companies Reporting Remarkable Results: WMT, LLY, CAH",
    "image": "https://images.financialmodelingprep.com/news/3-companies-reporting-remarkable-results-wmt-lly-cah-20240816.jpg",
    "site": "zacks.com",
    "text": "The 2024 Q2 earnings season is slowly grinding to a halt, with the vast majority of S&P 500 companies already delivering quarterly results. Peeking a bit ahead, earnings for the current period (2024 Q3) are expected to be up 4.3% on 4.6% higher revenues, chaining together consecutive periods of positivity.",
    "url": "https://www.zacks.com/commentary/2322741/3-companies-reporting-remarkable-results-wmt-lly-cah?cid=CS-STOCKNEWSAPI-FT-investment_ideas-2322741",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-16T11:16:05-04:00",
    "date_et": "2024-08-16"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-16 13:21:11",
    "publisher": "Zacks Investment Research",
    "title": "Why Lilly (LLY) Might be Well Poised for a Surge",
    "image": "https://images.financialmodelingprep.com/news/why-lilly-lly-might-be-well-poised-for-a-20240816.jpg",
    "site": "zacks.com",
    "text": "Lilly (LLY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.",
    "url": "https://www.zacks.com/stock/news/2323318/why-lilly-lly-might-be-well-poised-for-a-surge?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_8-2323318",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-16T13:21:11-04:00",
    "date_et": "2024-08-16"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-16 16:15:00",
    "publisher": "PRNewsWire",
    "title": "Lilly announces retirement of Marschall S. Runge from its Board of Directors",
    "image": "https://images.financialmodelingprep.com/news/lilly-announces-retirement-of-marschall-s-runge-from-its-20240816.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge, M.D.",
    "url": "https://www.prnewswire.com/news-releases/lilly-announces-retirement-of-marschall-s-runge-from-its-board-of-directors-302224526.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-16T16:15:00-04:00",
    "date_et": "2024-08-16"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-18 09:00:00",
    "publisher": "Seeking Alpha",
    "title": "Our Top 10 Dividend Growth Stocks - August 2024",
    "image": "https://images.financialmodelingprep.com/news/our-top-10-dividend-growth-stocks-august-2024-20240818.jpg",
    "site": "seekingalpha.com",
    "text": "This article focuses on selecting high-growth dividend stocks with rapidly growing dividends rather than high current yields. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks. It offers a step-by-step guide on structuring a portfolio based on this strategy.",
    "url": "https://seekingalpha.com/article/4715183-our-top-10-dividend-growth-stocks-august-2024",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-18T09:00:00-04:00",
    "date_et": "2024-08-18"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-18 12:05:00",
    "publisher": "The Motley Fool",
    "title": "Prediction: This Hypergrowth Company Could Be the Next Trillion-Dollar Stock",
    "image": "https://images.financialmodelingprep.com/news/prediction-this-hypergrowth-company-could-be-the-next-trilliondollar-20240818.jpg",
    "site": "fool.com",
    "text": "Eli Lilly is one of a few corporations close to hitting the $1 trillion mark. Despite a rich-looking valuation, the company should continue delivering strong returns.",
    "url": "https://www.fool.com/investing/2024/08/18/prediction-this-hypergrowth-company-could-be-the-n/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-18T12:05:00-04:00",
    "date_et": "2024-08-18"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-18 14:10:00",
    "publisher": "The Motley Fool",
    "title": "Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived",
    "image": "https://images.financialmodelingprep.com/news/forget-mounjaro-eli-lillys-next-big-blockbuster-has-arrived-20240818.jpg",
    "site": "fool.com",
    "text": "Last November, Eli Lilly received FDA approval for obesity drug Zepbound. In the second quarter, Zepbound generated over $1.2 billion in revenue!",
    "url": "https://www.fool.com/investing/2024/08/18/forget-mounjaro-eli-lillys-next-big-blockbuster-ha/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-18T14:10:00-04:00",
    "date_et": "2024-08-18"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-19 04:22:21",
    "publisher": "Finbold",
    "title": "2 Goldman Sach stocks to turn $100 to $1000 by 2025",
    "image": "https://images.financialmodelingprep.com/news/2-goldman-sach-stocks-to-turn-100-to-1000-20240819.jpg",
    "site": "finbold.com",
    "text": "Banking giant Goldman Sachs (NYSE: GS) has identified several stocks likely to witness an upside in the future based on their key fundamentals.",
    "url": "https://finbold.com/2-goldman-sach-stocks-to-turn-100-to-1000-by-2025/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-19T04:22:21-04:00",
    "date_et": "2024-08-19"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-19 05:11:00",
    "publisher": "The Motley Fool",
    "title": "Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond",
    "image": "https://images.financialmodelingprep.com/news/prediction-these-2-unstoppable-pharma-stocks-will-continue-to-20240819.jpg",
    "site": "fool.com",
    "text": "Novo Nordisk and Eli Lilly won't be constrained by manufacturing too much longer. That means they'll sell more of their in-demand drugs.",
    "url": "https://www.fool.com/investing/2024/08/19/prediction-these-2-unstoppable-pharma-stocks-will/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-19T05:11:00-04:00",
    "date_et": "2024-08-19"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-19 13:49:30",
    "publisher": "Benzinga",
    "title": "Three Biotech Stocks to Buy for the \"Golden Age of Medicine\"",
    "image": "https://images.financialmodelingprep.com/news/three-biotech-stocks-to-buy-for-the-golden-age-20240819.jpg",
    "site": "benzinga.com",
    "text": "A year ago, medical experts and Nobel Laureates interviewed by The New York Times proclaimed \"a Golden Age of Medicine\" is here.",
    "url": "https://www.benzinga.com/personal-finance/24/08/40446326/three-biotech-stocks-to-buy-for-the-golden-age-of-medicine",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-19T13:49:30-04:00",
    "date_et": "2024-08-19"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-19 13:57:57",
    "publisher": "Invezz",
    "title": "Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings",
    "image": "https://images.financialmodelingprep.com/news/top-10-pharmaceutical-companies-in-2024-sp-globals-latest-ratings-20240819.jpg",
    "site": "invezz.com",
    "text": "In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.",
    "url": "https://invezz.com/news/2024/08/19/top-10-pharmaceutical-companies-in-2024-sp-globals-latest-ratings-and-rankings/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-19T13:57:57-04:00",
    "date_et": "2024-08-19"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-20 06:45:01",
    "publisher": "CNBC",
    "title": "Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-weight-loss-drug-slashes-the-risk-of-developing-20240820.jpg",
    "site": "cnbc.com",
    "text": "Eli Lilly's weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with pre-diabetes compared to a placebo, according to initial results from a long-term study. The late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period.",
    "url": "https://www.cnbc.com/2024/08/20/eli-lilly-weight-loss-drug-cuts-risk-of-developing-diabetes-in-trial.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-20T06:45:01-04:00",
    "date_et": "2024-08-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-20 06:54:47",
    "publisher": "Reuters",
    "title": "Eli Lilly says weight-loss drug cut diabetes risk by 94% in trial",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-says-weightloss-drug-cut-diabetes-risk-by-20240820.jpg",
    "site": "reuters.com",
    "text": "Eli Lilly said on Tuesday its weight loss drug cut the risk of developing diabetes by 94% in patients with pre-diabetes or those who were obese or overweight in a long-term study.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-says-weight-loss-drug-cut-diabetes-risk-by-94-trial-2024-08-20/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-20T06:54:47-04:00",
    "date_et": "2024-08-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-20 08:47:00",
    "publisher": "Market Watch",
    "title": "Eli Lilly's Mounjaro cuts risk of developing Type 2 diabetes, study finds",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-mounjaro-cuts-risk-of-developing-type-2-20240820.jpg",
    "site": "marketwatch.com",
    "text": "Eli Lilly & Co.'s stock LLY gained more than 2% premarket on Tuesday after the drugmaker said that tirzepatide, marketed as the diabetes drug Mounjaro and weight-loss treatment Zepbound, sharply cut patients' risk of developing Type 2 diabetes in a late-stage trial.",
    "url": "https://www.marketwatch.com/story/eli-lillys-mounjaro-cuts-risk-of-developing-type-2-diabetes-study-finds-dcb878be",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-20T08:47:00-04:00",
    "date_et": "2024-08-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-20 09:56:54",
    "publisher": "Invezz",
    "title": "Eli Lilly's weight-loss pill shows 94% reduction in diabetes risk: Is a $1 trillion valuation next?",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-weightloss-pill-shows-94-reduction-in-diabetes-20240820.jpg",
    "site": "invezz.com",
    "text": "Eli Lilly & Co (NYSE: LLY) has made a groundbreaking revelation that its weight-loss drug, Tirzepatide, reduces the risk of developing type 2 diabetes by an astonishing 94% in overweight adults with pre-diabetes.",
    "url": "https://invezz.com/news/2024/08/20/eli-lillys-weight-loss-pill-shows-94-reduction-in-diabetes-risk-is-a-1-trillion-valuation-next/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-20T09:56:54-04:00",
    "date_et": "2024-08-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-20 10:06:50",
    "publisher": "Schaeffers Research",
    "title": "Preliminary Late-Stage Study Boosts Eli Lilly Stock",
    "image": "https://images.financialmodelingprep.com/news/preliminary-latestage-study-boosts-eli-lilly-stock-20240820.jpg",
    "site": "schaeffersresearch.com",
    "text": "Eli Lilly And Co (NYSE:LLY) announced today preliminary results from a late-stage study indicated the main ingredients Zepbound and Mounjaro of weight-loss drug tirzepatide reduced the risk of progression to type 2 diabetes by 94%.",
    "url": "https://www.schaeffersresearch.com/content/news/2024/08/20/preliminary-late-stage-study-boosts-eli-lilly-stock",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-20T10:06:50-04:00",
    "date_et": "2024-08-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-20 12:00:51",
    "publisher": "Investopedia",
    "title": "Why Eli Lilly Stock Jumped to a Record High on Tuesday",
    "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-stock-jumped-to-a-record-high-20240820.jpg",
    "site": "investopedia.com",
    "text": "Eli Lilly (LLY) stock jumped to a record high on Tuesday after clinical trial results showed tirzepatide—the active ingredient in Lilly's injectable weight-loss drug Zepbound and diabetes treatment Mounjaro—lowered patients' risk of developing type 2 diabetes by 94%.",
    "url": "https://www.investopedia.com/eli-lilly-stock-price-record-high-weight-loss-drug-diabetes-8698079",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-20T12:00:51-04:00",
    "date_et": "2024-08-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-20 15:12:48",
    "publisher": "Seeking Alpha",
    "title": "Eli Lilly: Tirzepatide's Winning Streak Continues",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-tirzepatides-winning-streak-continues-20240820.jpg",
    "site": "seekingalpha.com",
    "text": "Eli Lilly's key growth product tirzepatide (Mounjaro/Zepbound) continues to deliver on both fronts. Increased supply visibility led to a $3 billion increase in the full-year total revenue guidance range. After strong Q2 results, Eli Lilly reported positive long-term data from the SURMOUNT-1 trial, showing long-term treatment with tirzepatide significantly reduced the risk of onset of type 2 diabetes.",
    "url": "https://seekingalpha.com/article/4715965-eli-lilly-tirzepatides-winning-streak-continues",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-20T15:12:48-04:00",
    "date_et": "2024-08-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-20 16:46:42",
    "publisher": "The Motley Fool",
    "title": "Why Eli Lilly Topped the Market on Tuesday",
    "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-topped-the-market-on-tuesday-20240820.jpg",
    "site": "fool.com",
    "text": "The pharmaceutical giant has been investigating its Zepbound/Mounjaro drug for various indications. It performed very well in its latest diabetes and weight loss study.",
    "url": "https://www.fool.com/investing/2024/08/20/why-eli-lilly-topped-the-market-on-tuesday/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-20T16:46:42-04:00",
    "date_et": "2024-08-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-20 19:07:18",
    "publisher": "Fox Business",
    "title": "Eli Lilly's Zepbound reduces type 2 diabetes risk, study shows",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-zepbound-reduces-type-2-diabetes-risk-study-20240820.jpg",
    "site": "foxbusiness.com",
    "text": "Eli Lilly announced results of a study in which weekly shots of tirzepatide injections significantly reduced the risk of progression to type 2 diabetes by 94% among certain adults.",
    "url": "https://www.foxbusiness.com/lifestyle/eli-lillys-zepbound-reduces-type-2-diabetes-risk-study-shows",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-20T19:07:18-04:00",
    "date_et": "2024-08-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-21 04:36:00",
    "publisher": "The Motley Fool",
    "title": "Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-could-soar-to-1150-according-to-20240821.jpg",
    "site": "fool.com",
    "text": "Bank of America's price target for Eli Lilly implies a gain of about 25% from the stock's recent closing price. Eli Lilly's blockbuster weight management drug is gaining market share at a rapid pace.",
    "url": "https://www.fool.com/investing/2024/08/21/eli-lilly-stock-could-soar-to-1150-according-to-a/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-21T04:36:00-04:00",
    "date_et": "2024-08-21"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-21 08:06:24",
    "publisher": "Investopedia",
    "title": "Watch These Eli Lilly Price Levels as Stock Sets Record High on Trial Results",
    "image": "https://images.financialmodelingprep.com/news/watch-these-eli-lilly-price-levels-as-stock-sets-20240821.jpg",
    "site": "investopedia.com",
    "text": "Eli Lilly (LLY) shares set a record high on Tuesday after announcing that clinical trials of tirzepatide, the medicine used in the company's diabetes drug Mounjaro and injectable weight loss treatment Zepbound, significantly reduced the risk of developing type 2 diabetes in patients.",
    "url": "https://www.investopedia.com/eli-lilly-stock-price-levels-to-watch-record-high-8699066",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-21T08:06:24-04:00",
    "date_et": "2024-08-21"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-21 08:51:04",
    "publisher": "Benzinga",
    "title": "Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle",
    "image": "https://images.financialmodelingprep.com/news/novo-nordisk-vs-eli-lilly-beyond-the-weightloss-drug-20240821.jpg",
    "site": "benzinga.com",
    "text": "The rivalry between Novo Nordisk A/S NVO and Eli Lilly and Co LLY has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments.",
    "url": "https://www.benzinga.com/general/biotech/24/08/40484188/novo-nordisk-vs-eli-lilly-beyond-the-weight-loss-drug-battle",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-21T08:51:04-04:00",
    "date_et": "2024-08-21"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-21 11:41:32",
    "publisher": "Zacks Investment Research",
    "title": "Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk",
    "image": "https://images.financialmodelingprep.com/news/lilly-lly-up-3-on-obesity-drug-cutting-diabetes-20240821.jpg",
    "site": "zacks.com",
    "text": "Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.",
    "url": "https://www.zacks.com/stock/news/2325158/lilly-lly-up-3-on-obesity-drug-cutting-diabetes-risk?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2325158",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-21T11:41:32-04:00",
    "date_et": "2024-08-21"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-22 06:17:00",
    "publisher": "The Motley Fool",
    "title": "This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club",
    "image": "https://images.financialmodelingprep.com/news/this-undervalued-stock-could-join-the-race-with-eli-20240822.jpg",
    "site": "fool.com",
    "text": "Eli Lilly's weight loss drugs are pushing the company's market cap toward $1 trillion. Johnson & Johnson is the global leader in drug sales, but its market cap is under $400 billion.",
    "url": "https://www.fool.com/investing/2024/08/22/this-undervalued-stock-could-join-the-race-with-el/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-22T06:17:00-04:00",
    "date_et": "2024-08-22"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-22 06:45:00",
    "publisher": "The Motley Fool",
    "title": "Eli Lilly's Growth Rate Is Fantastic, but This Number Is Even Better",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-growth-rate-is-fantastic-but-this-number-20240822.jpg",
    "site": "fool.com",
    "text": "Eli Lilly's sales rose by 36% last quarter to $11.3 billion. The company's low cost of sales has boosted its bottom line at a much higher rate.",
    "url": "https://www.fool.com/investing/2024/08/22/eli-lillys-growth-rate-is-fantastic-but-this-numbe/",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-22T06:45:00-04:00",
    "date_et": "2024-08-22"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2024-08-22 10:00:00",
    "publisher": "PRNewsWire",
    "title": "Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference",
    "image": "https://images.financialmodelingprep.com/news/lilly-to-participate-in-morgan-stanley-22nd-annual-global-20240822.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS , Aug. 22, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 5, 2024. Jacob Van Naarden, executive vice president and president, Lilly Oncology, will participate in a fireside chat at 7:45 a.m.",
    "url": "https://www.prnewswire.com/news-releases/lilly-to-participate-in-morgan-stanley-22nd-annual-global-healthcare-conference-302227835.html",
    "ticker": "LLY",
    "event_date": "2024-08-08",
    "window_start": "2024-08-01",
    "window_end": "2024-08-22",
    "publishedDateET": "2024-08-22T10:00:00-04:00",
    "date_et": "2024-08-22"
  }
]